Location: Solmed Polyclinic (Zagreb), SB Medico (Rijeka)
Study Drug: Biological therapy, JAK-1 inhibitor. The drug is already registered for the treatment of atopic dermatitis in patients over 12 years old.
Main Inclusion Criteria: Children aged 6 months to 12 years diagnosed with atopic dermatitis for 3 months or more, who have insufficiently controlled disease despite standard therapy.
Status: In preparation
Start of patient enrollment: October 2024.
Planned completion of new patient enrollment: December 2026.
